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In the last decade, magnetic resonance imaging (MRI) with
the use of intravenous extracellular contrast agents (for example,
Gd-DTPA and Gd-DOTA) has been recognized as the noninvasive
diagnostic tool of choice in the evaluation of focal liver lesions(1–5)
thanks to the fact that it does not require ionizing radiation in
association with its high spatial resolution and excellent tissue
contrast; its capability to study the vascular behavior of the lesion
and to detect the presence of fat component in the lesion, besides
allowing the differentiation of intrinsic tissue characteristics such
as relaxation time and distribution of water in the liver lesion as
well as in the surrounding parenchyma. Such aspects, among oth-
ers, have led MRI to be rated as a molecular imaging method(3).
However, despite those unquestionable advantages, MRI pre-
sents some limitations related to the differentiation of certain fo-
cal liver lesions in cirrhotic patients, such as focal nodular hyper-
plasia (FNH) versus adenoma and dysplastic nodule versus hepa-
tocellular carcinoma (HCC) whose imaging findings are similar to
each other but require distinctive approaches(6,7). Liver-specific
contrast agents have been introduced to overcome such limita-
tions and, among others, gadoxetic acid (Gd-EOB-DTPA)(8,9) that
was recently made commercially available in Brazil, can be men-
tioned.
Gadoxetic acid (or gadoxetate disodium) is a paramagnetic
contrast agent whose enhancement effect is mediated by a linear
ion complex formed by gadolinium and ethoxy benzyl-diethylene-
triaminepentaacetatic acid (EOB-DTPA). Because of the lipophilic
property of the EOB component (ethoxy benzyl) combined with the
DTPA hydrophilic property, the gadoxetic acid shows a two-phase
or two-compartmental distribution pattern, i.e., after injection, the
agent distributes into the vessels and extracellular spaces during
the dynamic phases of hepatic enhancement (arterial, portal and
equilibrium phases) and later on shows progressive hepatocytes
uptake and subsequent complete renal and hepatobiliary excre-
tion in equivalent amount in cases where the liver and kidneys
function is preserved(8–10). Because of such a characteristic,
gadoxetic acid is considered to be a “mixed action” (extracellular
and hepatobiliary) contrast agent(9).
Thus, it provides not only information related to the extracel-
lular enhancement during the dynamic phases of hepatic perfu-
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sion, but also data related to the enhancement resulting from its
liver-specific properties during the hepatobiliary phase, which oc-
curs between ten and twenty minutes after intravenous contrast
injection(11). Therefore, the typical focal liver lesions enhancement
pattern observed during the dynamic perfusion phase is reproduced
with the utilization of gadoxetic acid(11). Additionally, as a func-
tion of the presence of its lipophilic component, there is a pro-
gressive contrast medium uptake by hepatocytes, and increase in
the signal intensity of the parenchyma on T1-weighted images
because of the shortening of T1 relaxation time, differently from
the behavior in the cells of most liver nodules where hepatocytes
are absent (for example, metastases and poorly differentiated HCCs),
allowing their differentiation from hepatocytic nodules (for example,
FNH, regenerative and dysplastic nodules)(11,12).
In the last years, several studies have demonstrated that the
use of gadoxetic acid is safe(13–15) and increases the MRI effec-
tiveness in the detection or diagnostic differentiation of several liver
nodules such as metastasis, HCC, adenomas and FNH(16–19), with
a performance superior or even complementary to extracellular con-
trast-enhanced computed tomography and MRI(20–22).
In this sense, the study developed by Francisco et al.(23) and
published in the present issue of Radiologia Brasileira, compre-
hensively approaching the role played by gadoxetic acid in the evalu-
ation of focal liver lesions, is welcome. In such study, the authors
clearly present the subject matter, describing the main features,
indications, ways of administration and an optimized protocol for
cases where the liver-specific (or hepatobiliary) contrast agent is
adopted, besides describing its influence on the diagnosis of the
different types of focal liver lesions.
Despite the higher cost as compared with other widely avail-
able extracellular contrast agents, besides the necessity of a more
elaborate injection technique to get satisfactory results, and based
on the findings of many published studies, it is our opinion that the
use of gadoxetic acid is safe and justified to differentiate between
adenoma and FNH, between HCC and dysplastic nodule, or to iden-
tify small primary or secondary, malignant lesions (< 2 cm). We
hope that, in the near future, the scientific societies’ guidelines
contemplate liver-specific contrast-enhanced MRI as a valid alter-
native included in the diagnostic algorithm of several focal liver
lesions(24–26).
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